Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC

BACKGROUND: No biomarker is available to predict prognosis of patients with advanced ovarian cancer (AOC) and guide the choice of chemotherapy. We performed a prospective-retrospective biomarker study within the MITO2 trial on the treatment of AOC. Patients and methods: MITO2 is a randomised multice...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Perrone, Francesco, Baldassarre, Gustavo, Indraccolo, Stefano, Signoriello, Simona, Chiappetta, Gennaro, Esposito, Franca, Ferrandina, Gabriella, Franco, Renato, Mezzanzanica, Delia, Sonego, Maura, Zulato, Elisabetta, Zannoni, Gian F., Canzonieri, Vincenzo, Scambia, Giovanni, Sorio, Roberto, Savarese, Antonella, Breda, Enrico, Scollo, Paolo, Ferro, Antonella, Tamberi, Stefano, Febbraro, Antonio, Natale, Donato, Maio, Massimo Di, Califano, Daniela, Scognamiglio, Giosuè, Lorusso, Domenica, Canevari, Silvana, Losito, Simona, Gallo, Ciro, Pignata, Sandro
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5341934/
https://ncbi.nlm.nih.gov/pubmed/27655643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12056
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares